A Phase 1/2 Study to Evaluate the Safety and Efficacy of Intravitreal Administration of BS01 in Patients With Geographic Atrophy Secondary to Dry AMD

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2031

Conditions

Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD)

Interventions

BIOLOGICAL

BS01

a recombinant adeno-associated virus vector expressing ChronosFP (AAV2-CAGChronosFP)

OTHER

Sham procedure control

Sham procedure without needle